Alkermes (ALKS) Net Income towards Common Stockholders (2010 - 2026)
Alkermes' (ALKS) quarterly Net Income towards Common Stockholders came in at -$66.5 million in Q1 2026, down 168.87% on a QoQ basis from $96.6 million in Q4 2025.
Alkermes (ALKS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$66.5 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders changed N/A year-over-year to -$66.5 million in Q1 2026; TTM through Mar 2026 was $30.1 million, a 904.79% increase from a year earlier, with the FY2025 full-year figure at $288.9 million, up 5090.05% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$66.5 million, down from $96.6 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for ALKS reached as high as $96.6 million in Q4 2025 and fell as low as -$66.5 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$13.1 million across 5 years, with a median of -$33.0 million in 2022.
- Across the five-year window, Net Income towards Common Stockholders tumbled 1374.79% in 2022 and soared 219447.73% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at $87.7 million in 2022, then sank by 146.58% to -$40.9 million in 2023, then jumped by 100.11% to $44000.0 in 2024, then surged by 219447.73% to $96.6 million in 2025, then slumped by 168.87% to -$66.5 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$66.5 million in Q1 2026, $96.6 million in Q4 2025, and $44000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Alkermes | 8.78 Bn | 8.27 Bn | 331.33 Mn | -66.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.53 Mn |
| Dec 31, 2025 | 96.60 Mn |
| Dec 31, 2024 | 44,000.00 |
| Sep 30, 2024 | -481,000.00 |
| Jun 30, 2024 | -3.30 Mn |
| Mar 31, 2024 | -2.12 Mn |
| Dec 31, 2023 | -40.86 Mn |
| Sep 30, 2023 | -45.35 Mn |
| Jun 30, 2023 | -42.04 Mn |
| Mar 31, 2023 | -36.52 Mn |
| Dec 31, 2022 | 87.72 Mn |
| Sep 30, 2022 | -63.97 Mn |
| Jun 30, 2022 | -30.14 Mn |
| Mar 31, 2022 | -35.90 Mn |
| Dec 31, 2021 | 137.03 Mn |
| Sep 30, 2021 | -28.99 Mn |
| Jun 30, 2021 | 2.36 Mn |
| Mar 31, 2021 | -22.42 Mn |
| Dec 31, 2020 | -29.62 Mn |
| Sep 30, 2020 | -134,000.00 |